{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:25:49Z","timestamp":1784640349882,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clml.2019.12.016","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:15:24Z","timestamp":1580429724000},"page":"e461-e467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Does Outcome\/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13?\u00a0Results From a Pilot Study"],"prefix":"10.1016","volume":"20","author":[{"given":"Roberto","family":"Castelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Bergamaschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Teatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cilumbriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Schiavon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gallipoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Lambertenghi","family":"Deliliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.12.016_bib1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/jcp.25887","article-title":"A\u00a0biophysical view on von Willebrand factor activation","volume":"233","author":"L\u00f6f","year":"2018","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.clml.2019.12.016_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5482\/HAMO-14-12-0081","article-title":"Interaction of von Willebrand factor with platelets and the vessel wall","volume":"35","author":"Ruggeri","year":"2015","journal-title":"Hemostaseologie"},{"key":"10.1016\/j.clml.2019.12.016_bib3","first-page":"161","article-title":"Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor","volume":"59","author":"Hoylaerts","year":"1997","journal-title":"Verh K Acad Geneeskd Belg"},{"key":"10.1016\/j.clml.2019.12.016_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.clml.2019.12.016_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mvr.2012.05.004","article-title":"ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis","volume":"84","author":"Lee","year":"2012","journal-title":"Microvasc Res"},{"key":"10.1016\/j.clml.2019.12.016_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000314579","article-title":"Thrombotic microangiopathies: from animal models to human disease and cure","volume":"169","author":"Caprioli","year":"2011","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.clml.2019.12.016_bib7","first-page":"2","article-title":"Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis","volume":"14","author":"Laurence","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2019.12.016_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1160\/TH04-07-0450","article-title":"Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies","volume":"93","author":"Ruiz-Torres","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2019.12.016_bib9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.bbmt.2017.05.013","article-title":"Acquired complement regulatory gene mutations and hematopoietic stem cell transplant\u2013related thrombotic microangiopathy","volume":"23","author":"Ardissino","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2019.12.016_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.clml.2014.05.003","article-title":"Thrombosis and hemostatic abnormalities in hematological malignancies","volume":"14","author":"Colombo","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.12.016_bib11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/157016110791330799","article-title":"Thromboembolic complications in malignant haematological disorders","volume":"8","author":"Castelli","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.clml.2019.12.016_bib12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0889-8588(05)70348-8","article-title":"Thrombotic microangiopathies associated with drugs and bone marrow transplantation","volume":"10","author":"Moake","year":"1996","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2019.12.016_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.leukres.2016.12.004","article-title":"Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients","volume":"53","author":"Liu","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.12.016_bib14","first-page":"454","article-title":"Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease)","volume":"88","author":"Mannucci","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.12.016_bib15","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.thromres.2018.01.014","article-title":"Thrombotic microangiopathy in cancer","volume":"164","author":"Weitz","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.clml.2019.12.016_bib16","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1515\/cclm-2015-0789","article-title":"Laboratory and clinical risk assessment to treat myelodysplatic syndromes","volume":"54","author":"Gidaro","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.clml.2019.12.016_bib17","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1182\/blood-2012-04-423046","article-title":"Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS","volume":"120","author":"Deeg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.016_bib18","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.18.02142","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update","volume":"37","author":"Bohlius","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.016_bib19","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00277-014-2070-8","article-title":"Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function","volume":"93","author":"Castelli","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.12.016_bib20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.016_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1309\/AJCP5O3YBKTGGWNQ","article-title":"High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes","volume":"139","author":"Gianelli","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2019.12.016_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1160\/TH13-08-0688","article-title":"FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients","volume":"112","author":"Mancini","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clml.2019.12.016_bib23","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood.V98.6.1842","article-title":"Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders","volume":"98","author":"Moore","year":"2001","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:48Z","timestamp":1761870888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502030001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S215226502030001X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Outcome\/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13?\u00a0Results From a Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}